Page ii (advert) |
Previous | 613 of 1065 | Next |
|
|
small (250x250 max)
medium (500x500 max)
Large
Extra Large
large ( > 500x500)
Full Resolution
|
Loading content ...
Motrin" Tablets(ibuprofen. Upjohn) Contraindications: Individuals hypersensitive to it, or with the syndrome of nasal polyps, angioedema, and bronchospastic reactivity to aspirin, iodides, or other nonsteroidal anti-inflammatory agents. Anaphylactoid reactions have occurred in such patients. Warnings: Peptic ulceration and gastrointestinal bleeding, sometimes severe, have been reported. Ulceration, perforation, and bleeding may end fatally. An association has not been established. Motrin should be given under close supervision to patients wtU a history of upper gastrointestinal tract disease, only after consulting ADVERSE REACTIONS. In patients with active peptic ulcer and active rheumatoid arthritis, nonulcerogenic drugs, such as gold, should be tried. If Motrin must be given, the patient should be under close supervision for signs of ulcer perforation or gastrointestinal bleeding. Chronic studies in rats and monkeys have show/n mild renal toxicity characterized by papillary edema and necrosis. Renal papillary necrosis has rarely been shov/n in humans treated with Motrin. Precautions: Blurred and/or diminished vision, scotomata. and/or changes in color vision have been reported. If these develop, discontinue Motrin and the patient should have an ophthalmologic examination, including central visual fields and color vision testing. Fluid retention and edema have been associated with Motrin; use with caution in patients with a history of cardiac decompensation or hypertension. Motrin is excreted mainly by the kidneys. In patients with renal impairment, reduced dosage may be necessary. Prospective studies of /Wofr/V?.safety in patients with chronic renal failure have not been done. Motrin can inhibit platelet aggregation and prolong bleeding time. Use with caution in persons with intrinsic coagulation defects and those on anticoagulant therapy. Patients should report signs or symptoms of gastrointestinal ulceration or bleeding, blurred vision or other eye symptoms, skin rash, weight gam. or edema. To avoid exacerbation of disease or adrenal insufficiency, patients on prolonged corticosteroid therapy should have therapy tapered slowly when Motrin is added. The antipyretic, anti-inflammatory activity of Motrin may mask inflammation and fever. Drug Interactions. Aspirin: used concomitantly may decrease Motrin blood levels. Coumar/n; bleeding has been reported in patients taking Motrin and coumarin. Pregnancy and nursing mothers: Motrin should not be taken during pregnancy nor by nursing mothers. Adverse Reactions The most frequent type of adverse reaction occurring with Motrin is gastrointestinal, of which one or more occurred in 4% to 16% of the patients. Incidence Greater Ttian 1% (but less tf}an 3%) -Probable Causal Relationship Gastrointestinal: Nauseaf epigastric pain" heartburnf diarrhea, abdominal distress, nausea and vomiting, indigestion, constipation, abdominal cramps or pain, fullness of 61 tract {bloating and flatulence); Central Nervous System: Dizziness:' headache, nervousness; Dermatologic: Rash* (including maculopapular type), pruritus; Special Senses: Tinnitus; Metabolic/Endocrine: Decreased appetite; Cardiovascular: Edema, fluid retention (generally responds promptly to drug discontinuation; see PRECAUTIONS). Incidence Less Than 1%-Probable Causal Relationship** Gastrointestinal: Gastric or duodenal ulcer with bleeding and/or perforation, gastrointestinal hemorrhage, melena. gastritis, hepatitis, jaundice, abnormal liver function tests; Central Nervous System: Depression, insomnia, confusion, emotional lability, somnolence, aseptic meningitis with fever and coma; Dermatologic: Vesiculobullous eruptions, urticaria. erythema multiforme. Stevens-Johnson syndrome, alopecia. Special Senses: Hearing loss, amblyopia (blurred and/or diminished vision, scotomata, and/or changes in color vision) (see PRECAUTIONS); Hematologic: Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia (sometimes Coombs' positive), thrombocytopenia with or without purpura, eosinophilia. decreases in hemoglobin and hematocrit; Cardiovascular: Congestive heart failure in patients with marginal cardiac function, elevated blood pressure, palpitations; Allergic: Syndrome of abdominal pain, fever, chills, nausea and vomiting, anaphylaxis, bronchospasm (see CONTRAINDICATIONS); Renal: Acute renal failure in patients with preexisting, significantly impaired renal function, decreased creatinine clearance, polyuria, azotemia, cystitis, hematuria, Pfliscellaneous: Dry eyes and mouth, gingival ulcer, rhinitis. Incidence Less Than 1%~Causal Relationship Unknown'* Gastrointestinal: Pancreatitis; Central Nervous System: Paresthesias, hallucinations, dream abnormalities, pseudotumor cerebri; Dermatologic: Toxic epidermal necrolysis, photoallergic skin reactions, Special Senses: Conjunctivitis, diplopia, optic neuritis; Hematologic: Bleeding episodes (e.g.. epistaxis. menorrhagia); IVletabolic/Endocrine: Gynecomastia, hypoglycemic reaction; Cardiovascular: Arrhythmia (sinus tachycardia, sinus bradycardia); Allergic: Serum sickness, lupus erytfiematosus syndrome, Henoch-Schbnlein vasculitis; Renal: Renal papillary necrosis, ^Reactions occurring in 3% to 9% of patients treated with Motrin. (Those reactions occurring in less than 3% of the patients are unmarked.) '^Reactions are classified under "Probable Causal Relationship" (PCR) if there has been one positive rechallenge or if three or more cases occur which might be causally related. Reactions are classified under "Causal Relationship Unknown" if seven or more events have been reported but the criteria for PCR have not been met. Overdosage: In cases of acute overdosage, the stomach should be emptied. The drug IS acidic and excreted m the urine, so alkaline diuresis may be beneficial. Dosage and Administration: Do not exceed 2400 mg per day. If gastrointestinal complaints occur, administer with meals or milk. Rheumatoid arthritis and osteoarthritis, including flares of chronic disease: Suggested dosage is 300,400, or 600 mg t.i.d. or q i.d. Mild to moderate pain: 400 mg every 4 to 6 hours as necessary for relief of pain. Caution: Federal law prohibits dispensing without prescription. MED B-5-S THE UPJOHN COMPANY Kalamazoo. Michigan 49001 USA A Public Service of This Magazine (Sl The Advertising Council Upjohn J-9042-4 July1981
Object Description
Rating | |
Fixed Title * | NCHH-17: North Carolina Medical Journal [1940-Present] |
Document Title | North Carolina Medical Journal [1940-Present] |
Subject Topical Other | Public Health -- Periodicals.; Physicians -- North Carolina -- Directory.; Societies, Medical -- North Carolina -- Periodicals. |
Description | Includes Transactions of the Society, -1960; 1961- , Transactions issued separately, bound in.; Includes Transactions of the auxiliary to the Medical Society of the State of North Carolina and Proceedings of the North Carolina Public Health Association. Official organ of the Medical Society of the State of North Carolina, 1940-May 1972; of the North Carolina Medical Society, June 1972-. Vols. for 1940-May 1972 published by the Medical Society of the State of North Carolina; June 1972- by the North Carolina Medical Society. |
Contributor | Medical Society of the State of North Carolina. Transactions.; Medical Society of the State of North Carolina.; North Carolina Medical Society.; North Carolina Medical Society. Transactions.; North Carolina Public Health Association. Proceedings. |
Publisher | [Winston-Salem] : North Carolina Medical Society [etc.], 1940- |
Repository | University of North Carolina at Chapel Hill. Health Sciences Library. |
Host | University of North Carolina at Chapel Hill |
Date | 1981 |
Identifier | NCHH-17-042 |
Form General | Periodicals |
Language | English |
Rights | This item is part of the North Carolina History of Health Digital Collection. Some materials in the Collection are protected by U.S. copyright law. This item is presented by the Health Sciences Library of the University of North Carolina at Chapel Hill for research and educational purposes. It may not be republished or distributed without permission of the Health Sciences Library. |
Digital Collection | North Carolina History of Health Digital Collection |
Sponsor | The North Carolina History of Health Digital Collection is an open access publishing initiative of the Health Sciences Library of the University of North Carolina at Chapel Hill. Financial support for the initiative was provided in part by a multi-year NC ECHO (Exploring Cultural Heritage Online) digitization grant, awarded by the State Library of North Carolina, and funded through the Library Services and Technology Act (LSTA). |
Volume Number | 42 |
Health Discipline | Medicine |
Digital Format | JPEG 2000 |
Print / Download PDF Version | http://archives.hsl.unc.edu/nchh/nchh-17/nchh-17-042.pdf |
Document Sort | all; nchh-17 |
Volume Link | http://dc.lib.unc.edu/cdm/search/collection/nchh/field/identi/searchterm/NCHH-17-042 |
Title Link | http://dc.lib.unc.edu/cdm/search/collection/nchh/field/documa/searchterm/NCHH-17 |
Catalog Record link | http://search.lib.unc.edu/search?R=UNCb1306322 |
Revision History | done |
Description
Fixed Title * | Page ii (advert) |
Document Title | North Carolina Medical Journal [1940-Present] |
Subject Topical Other | Public Health -- Periodicals.; Physicians -- North Carolina -- Directory.; Societies, Medical -- North Carolina -- Periodicals. |
Description | Includes Transactions of the Society, -1960; 1961- , Transactions issued separately, bound in.; Includes Transactions of the auxiliary to the Medical Society of the State of North Carolina and Proceedings of the North Carolina Public Health Association. Official organ of the Medical Society of the State of North Carolina, 1940-May 1972; of the North Carolina Medical Society, June 1972-. Vols. for 1940-May 1972 published by the Medical Society of the State of North Carolina; June 1972- by the North Carolina Medical Society. |
Contributor | Medical Society of the State of North Carolina. Transactions.; Medical Society of the State of North Carolina.; North Carolina Medical Society.; North Carolina Medical Society. Transactions.; North Carolina Public Health Association. Proceedings. |
Publisher | [Winston-Salem] : North Carolina Medical Society [etc.], 1940- |
Repository | University of North Carolina at Chapel Hill. Health Sciences Library. |
Host | University of North Carolina at Chapel Hill |
Date | 1981 |
Identifier | NCHH-17-042-0148 |
Form General | Periodicals |
Page Type | all; all images; advertisement |
Language | English |
Rights | This item is part of the North Carolina History of Health Digital Collection. Some materials in the Collection are protected by U.S. copyright law. This item is presented by the Health Sciences Library of the University of North Carolina at Chapel Hill for research and educational purposes. It may not be republished or distributed without permission of the Health Sciences Library. |
Filename | ncmed421981mediv2_0148.jp2 |
Digital Collection | North Carolina History of Health Digital Collection |
Sponsor | The North Carolina History of Health Digital Collection is an open access publishing initiative of the Health Sciences Library of the University of North Carolina at Chapel Hill. Financial support for the initiative was provided in part by a multi-year NC ECHO (Exploring Cultural Heritage Online) digitization grant, awarded by the State Library of North Carolina, and funded through the Library Services and Technology Act (LSTA). |
Volume Number | 42 |
Issue Number | 8 |
Page Number | ii |
Health Discipline | Medicine |
Full Text | Motrin" Tablets(ibuprofen. Upjohn) Contraindications: Individuals hypersensitive to it, or with the syndrome of nasal polyps, angioedema, and bronchospastic reactivity to aspirin, iodides, or other nonsteroidal anti-inflammatory agents. Anaphylactoid reactions have occurred in such patients. Warnings: Peptic ulceration and gastrointestinal bleeding, sometimes severe, have been reported. Ulceration, perforation, and bleeding may end fatally. An association has not been established. Motrin should be given under close supervision to patients wtU a history of upper gastrointestinal tract disease, only after consulting ADVERSE REACTIONS. In patients with active peptic ulcer and active rheumatoid arthritis, nonulcerogenic drugs, such as gold, should be tried. If Motrin must be given, the patient should be under close supervision for signs of ulcer perforation or gastrointestinal bleeding. Chronic studies in rats and monkeys have show/n mild renal toxicity characterized by papillary edema and necrosis. Renal papillary necrosis has rarely been shov/n in humans treated with Motrin. Precautions: Blurred and/or diminished vision, scotomata. and/or changes in color vision have been reported. If these develop, discontinue Motrin and the patient should have an ophthalmologic examination, including central visual fields and color vision testing. Fluid retention and edema have been associated with Motrin; use with caution in patients with a history of cardiac decompensation or hypertension. Motrin is excreted mainly by the kidneys. In patients with renal impairment, reduced dosage may be necessary. Prospective studies of /Wofr/V?.safety in patients with chronic renal failure have not been done. Motrin can inhibit platelet aggregation and prolong bleeding time. Use with caution in persons with intrinsic coagulation defects and those on anticoagulant therapy. Patients should report signs or symptoms of gastrointestinal ulceration or bleeding, blurred vision or other eye symptoms, skin rash, weight gam. or edema. To avoid exacerbation of disease or adrenal insufficiency, patients on prolonged corticosteroid therapy should have therapy tapered slowly when Motrin is added. The antipyretic, anti-inflammatory activity of Motrin may mask inflammation and fever. Drug Interactions. Aspirin: used concomitantly may decrease Motrin blood levels. Coumar/n; bleeding has been reported in patients taking Motrin and coumarin. Pregnancy and nursing mothers: Motrin should not be taken during pregnancy nor by nursing mothers. Adverse Reactions The most frequent type of adverse reaction occurring with Motrin is gastrointestinal, of which one or more occurred in 4% to 16% of the patients. Incidence Greater Ttian 1% (but less tf}an 3%) -Probable Causal Relationship Gastrointestinal: Nauseaf epigastric pain" heartburnf diarrhea, abdominal distress, nausea and vomiting, indigestion, constipation, abdominal cramps or pain, fullness of 61 tract {bloating and flatulence); Central Nervous System: Dizziness:' headache, nervousness; Dermatologic: Rash* (including maculopapular type), pruritus; Special Senses: Tinnitus; Metabolic/Endocrine: Decreased appetite; Cardiovascular: Edema, fluid retention (generally responds promptly to drug discontinuation; see PRECAUTIONS). Incidence Less Than 1%-Probable Causal Relationship** Gastrointestinal: Gastric or duodenal ulcer with bleeding and/or perforation, gastrointestinal hemorrhage, melena. gastritis, hepatitis, jaundice, abnormal liver function tests; Central Nervous System: Depression, insomnia, confusion, emotional lability, somnolence, aseptic meningitis with fever and coma; Dermatologic: Vesiculobullous eruptions, urticaria. erythema multiforme. Stevens-Johnson syndrome, alopecia. Special Senses: Hearing loss, amblyopia (blurred and/or diminished vision, scotomata, and/or changes in color vision) (see PRECAUTIONS); Hematologic: Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia (sometimes Coombs' positive), thrombocytopenia with or without purpura, eosinophilia. decreases in hemoglobin and hematocrit; Cardiovascular: Congestive heart failure in patients with marginal cardiac function, elevated blood pressure, palpitations; Allergic: Syndrome of abdominal pain, fever, chills, nausea and vomiting, anaphylaxis, bronchospasm (see CONTRAINDICATIONS); Renal: Acute renal failure in patients with preexisting, significantly impaired renal function, decreased creatinine clearance, polyuria, azotemia, cystitis, hematuria, Pfliscellaneous: Dry eyes and mouth, gingival ulcer, rhinitis. Incidence Less Than 1%~Causal Relationship Unknown'* Gastrointestinal: Pancreatitis; Central Nervous System: Paresthesias, hallucinations, dream abnormalities, pseudotumor cerebri; Dermatologic: Toxic epidermal necrolysis, photoallergic skin reactions, Special Senses: Conjunctivitis, diplopia, optic neuritis; Hematologic: Bleeding episodes (e.g.. epistaxis. menorrhagia); IVletabolic/Endocrine: Gynecomastia, hypoglycemic reaction; Cardiovascular: Arrhythmia (sinus tachycardia, sinus bradycardia); Allergic: Serum sickness, lupus erytfiematosus syndrome, Henoch-Schbnlein vasculitis; Renal: Renal papillary necrosis, ^Reactions occurring in 3% to 9% of patients treated with Motrin. (Those reactions occurring in less than 3% of the patients are unmarked.) '^Reactions are classified under "Probable Causal Relationship" (PCR) if there has been one positive rechallenge or if three or more cases occur which might be causally related. Reactions are classified under "Causal Relationship Unknown" if seven or more events have been reported but the criteria for PCR have not been met. Overdosage: In cases of acute overdosage, the stomach should be emptied. The drug IS acidic and excreted m the urine, so alkaline diuresis may be beneficial. Dosage and Administration: Do not exceed 2400 mg per day. If gastrointestinal complaints occur, administer with meals or milk. Rheumatoid arthritis and osteoarthritis, including flares of chronic disease: Suggested dosage is 300,400, or 600 mg t.i.d. or q i.d. Mild to moderate pain: 400 mg every 4 to 6 hours as necessary for relief of pain. Caution: Federal law prohibits dispensing without prescription. MED B-5-S THE UPJOHN COMPANY Kalamazoo. Michigan 49001 USA A Public Service of This Magazine (Sl The Advertising Council Upjohn J-9042-4 July1981 |
Digital Format | JPEG 2000 |
Print / Download PDF Version | http://archives.hsl.unc.edu/nchh/nchh-17/nchh-17-042.pdf |
Document Sort | all; nchh-17 |
Volume Link | http://dc.lib.unc.edu/cdm/search/collection/nchh/field/identi/searchterm/NCHH-17-042 |
Title Link | http://dc.lib.unc.edu/cdm/search/collection/nchh/field/documa/searchterm/NCHH-17 |
Catalog Record link | http://search.lib.unc.edu/search?R=UNCb1306322 |
Revision History | done |
Tags
Comments
Post a Comment for Page ii (advert)